Download Sample
Add to CartGlobal Human Rotavirus Vaccine Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Type;
Rotarix, Rotateq, Rotavac, Rotavin-M1, Lanzhou Lamb, and Other.By End Use;
Hospitals & Clinics, Academic & Research, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Human Rotavirus Vaccine Market (USD Million), 2021 - 2031
In the year 2024, the Global Human Rotavirus Vaccine Market was valued at USD 11,329.70 million. The size of this market is expected to increase to USD 21,249.05 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 9.4%.
The global human rotavirus vaccine market is experiencing significant growth driven by the increasing emphasis on childhood immunization programs and the rising awareness of the importance of preventing rotavirus infections. Rotavirus is a leading cause of severe diarrhea and dehydration in infants and young children worldwide, resulting in significant morbidity and mortality, particularly in low- and middle-income countries. In response, governments, healthcare organizations, and international agencies are implementing vaccination campaigns to reduce the burden of rotavirus gastroenteritis and its associated complications. The widespread adoption of rotavirus vaccination as part of routine childhood immunization schedules is driving market expansion, with increasing vaccination coverage contributing to a decline in rotavirus-related hospitalizations and deaths.
Technological advancements in vaccine development and manufacturing are enhancing the efficacy, safety, and accessibility of human rotavirus vaccines. The introduction of live-attenuated oral rotavirus vaccines, such as Rotarix and RotaTeq, has revolutionized rotavirus prevention efforts by providing effective protection against multiple rotavirus strains. These vaccines have undergone rigorous testing and regulatory approval processes, demonstrating their safety and efficacy in large-scale clinical trials. Additionally, innovations in vaccine delivery systems, such as heat-stable formulations and needle-free administration devices, are addressing challenges related to vaccine storage, distribution, and administration in resource-limited settings, thereby facilitating broader vaccine coverage and improving global vaccine access.
Strategic partnerships and collaborations between governments, vaccine manufacturers, and international organizations are driving market growth and expanding access to human rotavirus vaccines in underserved regions. Initiatives such as the Gavi, the Vaccine Alliance, and the Rotavirus Vaccine Program are facilitating the introduction of rotavirus vaccination in low-income countries through subsidized vaccine procurement, technical assistance, and capacity-building efforts. Furthermore, advocacy efforts and public-private partnerships are raising awareness about the benefits of rotavirus vaccination and addressing barriers to vaccine uptake, including vaccine hesitancy and healthcare infrastructure limitations. As these collaborative efforts continue to strengthen, the global human rotavirus vaccine market is expected to witness sustained growth, contributing to the reduction of rotavirus-associated morbidity and mortality worldwide.
Global Human Rotavirus Vaccine Market Recent Developments
-
In 2017, the Serum Institute of India Pvt. Ltd. revealed the result of a clinical trial Phase 3 efficacy study of the rotavirus vaccine BRV-PV, ROTASIIL. The study has shown that the vaccine is safe, well tolerated, and provides significant efficacy against severe rotavirus gastroenteritis
-
Mexico, a decline of up to 50% in diarrhoeal deaths in children who belong to the age group of fewer than 5 years of age was attributed directly to the use of the vaccine and safeguard their health.
Segment Analysis
The global human rotavirus vaccine market has been segmented based on type, end use, and geography to provide a comprehensive understanding of market dynamics and cater to diverse consumer needs. In terms of type, the market encompasses live-attenuated oral rotavirus vaccines, which are the most widely used and effective vaccines for preventing rotavirus gastroenteritis in infants and young children. These vaccines, such as Rotarix and RotaTeq, offer protection against multiple rotavirus strains and are administered orally, making them convenient and well-tolerated by children. The availability of different vaccine formulations and dosing schedules provides flexibility for healthcare providers and vaccine recipients.
The end use segment of the market includes hospitals, clinics, and vaccination centers, where rotavirus vaccines are administered as part of routine childhood immunization programs or during catch-up vaccination campaigns. Healthcare facilities play a crucial role in vaccine delivery, storage, and administration, ensuring widespread vaccine coverage and compliance with immunization schedules. Additionally, the inclusion of vaccination centers and outreach programs in the end use segment reflects efforts to improve vaccine accessibility and reach underserved populations, particularly in low- and middle-income countries where the burden of rotavirus gastroenteritis is high.
Geographically, the global human rotavirus vaccine market is segmented into regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa to provide insights into regional trends, market dynamics, and growth opportunities. While developed regions such as North America and Europe have high vaccination coverage rates and well-established immunization programs, emerging economies in Asia Pacific and Latin America present significant growth opportunities due to increasing investments in healthcare infrastructure, rising awareness of rotavirus infections, and government-led vaccination initiatives. Understanding regional variations in disease burden, vaccination policies, and healthcare systems is essential for vaccine manufacturers, policymakers, and healthcare providers to develop targeted strategies and address unmet needs in rotavirus prevention and control efforts.
Global Human Rotavirus Vaccine Segment Analysis
In this report, the Global Human Rotavirus Vaccine Market has been segmented by Type, End Use and Geography.
Global Human Rotavirus Vaccine Market, Segmentation by Type
The Global Human Rotavirus Vaccine Market has been segmented by Type into Rotarix, Rotateq, Rotavac, Rotavin-M1, Lanzhou Lamb and Other.
The global human rotavirus vaccine market has been segmented by type into several key products, including Rotarix, Rotateq, Rotavac, Rotavin-M1, Lanzhou Lamb, and others. Rotarix and Rotateq are among the most widely used vaccines globally, offering protection against multiple strains of rotavirus. These vaccines, administered orally, have demonstrated high efficacy in preventing severe rotavirus gastroenteritis and reducing rotavirus-related hospitalizations and deaths in infants and young children. Rotavac, developed indigenously in India, is another important vaccine in the market, contributing to the prevention of rotavirus infections, particularly in low- and middle-income countries where the burden of rotavirus gastroenteritis is highest.
The market includes other vaccines such as Rotavin-M1 and Lanzhou Lamb, which are used in specific regions and countries. Rotavin-M1, for example, is licensed for use in Vietnam and has shown efficacy in preventing rotavirus gastroenteritis in Vietnamese children. Lanzhou Lamb is manufactured in China and has been approved for use in certain provinces in China and other countries. These vaccines contribute to the global efforts to control and prevent rotavirus infections, offering additional options for healthcare providers and policymakers to address the burden of rotavirus gastroenteritis in their respective regions.
Ongoing research and development efforts are leading to the introduction of new rotavirus vaccine candidates, as well as improvements in existing vaccines. These developments aim to enhance vaccine efficacy, broaden strain coverage, and address challenges such as vaccine storage and distribution. With continued advancements in vaccine technology and increasing investment in global immunization programs, the market for human rotavirus vaccines is expected to witness further expansion, offering hope for reducing the global burden of rotavirus gastroenteritis and improving child health outcomes worldwide.
Global Human Rotavirus Vaccine Market, Segmentation by End Use
The Global Human Rotavirus Vaccine Market has been segmented by End Use into Hospitals & Clinics, Academic And Research and Others.
The global human rotavirus vaccine market has been segmented by end use into hospitals & clinics, academic and research institutions, and others, reflecting the diverse settings where rotavirus vaccination programs are implemented and researched. Hospitals and clinics serve as primary points of healthcare delivery, where routine childhood immunization programs are often administered. These facilities play a crucial role in vaccinating infants and young children against rotavirus, offering vaccinations as part of routine immunization schedules or during pediatric appointments. The widespread adoption of rotavirus vaccines in hospitals and clinics contributes significantly to increasing vaccination coverage and reducing the incidence of rotavirus gastroenteritis worldwide.
Academic and research institutions play a vital role in advancing scientific knowledge and innovation in the field of rotavirus vaccines. These institutions engage in clinical trials, epidemiological studies, and vaccine development research to improve the safety, efficacy, and accessibility of rotavirus vaccines. Academic researchers collaborate with vaccine manufacturers, healthcare providers, and public health agencies to conduct preclinical and clinical studies, evaluate vaccine effectiveness, and address knowledge gaps related to rotavirus epidemiology and vaccine-induced immunity. By contributing to evidence-based vaccine policy recommendations and vaccine development efforts, academic and research institutions play a pivotal role in shaping global rotavirus vaccination strategies and public health initiatives.
Other end-use segments encompass a variety of settings where rotavirus vaccination activities may take place, including community health centers, vaccination campaigns, and non-governmental organizations (NGOs) involved in public health programs. These settings represent additional avenues for increasing vaccine access and coverage, particularly in underserved communities and regions with limited healthcare infrastructure. By leveraging partnerships and collaborations across multiple sectors, these organizations can enhance vaccine delivery, outreach, and education efforts, ensuring that rotavirus vaccines reach those who need them most. As efforts to expand rotavirus vaccination programs continue to evolve, diverse end-use settings will play critical roles in achieving global vaccination targets and reducing the burden of rotavirus-associated morbidity and mortality.
Global Human Rotavirus Vaccine Market, Segmentation by Geography
In this report, the Global Human Rotavirus Vaccine Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Human Rotavirus Vaccine Market Share (%), by Geographical Region, 2024
The global human rotavirus vaccine market exhibits varying market shares across different geographical regions, reflecting disparities in vaccine adoption rates, healthcare infrastructure, and disease burden. North America and Europe hold significant market shares, driven by well-established childhood immunization programs, high vaccination coverage rates, and robust healthcare systems. In these regions, rotavirus vaccines are included in routine childhood vaccination schedules, resulting in widespread vaccine uptake and a decline in rotavirus-related morbidity and mortality. Additionally, strong regulatory frameworks and public health initiatives support vaccine implementation efforts, contributing to the dominance of North America and Europe in the global market share.
In contrast, regions such as Asia Pacific and Latin America are witnessing increasing market shares as efforts to expand rotavirus vaccination programs gain momentum. These regions bear a substantial burden of rotavirus-associated morbidity and mortality, particularly among children under five years of age. As a result, governments and international organizations are prioritizing the introduction of rotavirus vaccines into national immunization programs to reduce the impact of rotavirus gastroenteritis on child health. Rising investments in healthcare infrastructure, vaccine procurement, and public health campaigns are driving growth in the Asia Pacific and Latin America regions, leading to expanding market shares in the global human rotavirus vaccine market.
Furthermore, Sub-Saharan Africa presents opportunities for market growth as efforts to improve vaccine access and coverage intensify. Despite facing challenges such as limited healthcare resources, vaccine cold chain requirements, and logistical barriers, initiatives led by organizations like Gavi, the Vaccine Alliance, are supporting the introduction of rotavirus vaccines in Sub-Saharan African countries. These efforts aim to address disparities in vaccine access and reduce the burden of rotavirus gastroenteritis in the region. As a result, Sub-Saharan Africa is expected to contribute to the increasing market share of human rotavirus vaccines globally, underscoring the importance of equitable vaccine distribution and access to achieve global health goals.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Human Rotavirus Vaccine Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Emphasis on Childhood Immunization Programs
- Rising Awareness of Rotavirus Infections
-
Technological Advancements in Vaccine Development-Technological advancements in vaccine development have been instrumental in shaping the landscape of the global human rotavirus vaccine market. Traditional methods of vaccine production have given way to more sophisticated techniques, leading to the development of highly efficacious and safe rotavirus vaccines. Live-attenuated oral vaccines, such as Rotarix and RotaTeq, have emerged as the cornerstone of rotavirus prevention efforts, offering protection against multiple rotavirus strains. These vaccines are developed using advanced biotechnological methods to attenuate the virulence of the virus while retaining its immunogenicity, ensuring robust protection against rotavirus gastroenteritis. Furthermore, advancements in vaccine formulation and delivery systems have addressed critical challenges associated with rotavirus vaccination, particularly in resource-limited settings. Heat-stable formulations have been developed to overcome issues related to vaccine storage and transportation in regions with unreliable cold chain infrastructure. Additionally, innovations in needle-free delivery devices and oral administration techniques have improved vaccine acceptance and accessibility, especially in populations with limited access to healthcare facilities. These technological advancements have expanded the reach of rotavirus vaccination programs, facilitating broader vaccine coverage and contributing to the reduction of rotavirus-related morbidity and mortality globally. Moreover, ongoing research and development efforts are focused on enhancing the efficacy, safety, and affordability of rotavirus vaccines through novel vaccine platforms and manufacturing processes. Novel vaccine candidates, including virus-like particles (VLPs) and recombinant subunit vaccines, are being explored as potential alternatives to live-attenuated vaccines, offering advantages such as improved safety profiles and simplified manufacturing processes. Furthermore, advancements in adjuvant technology and antigen design are aimed at enhancing vaccine immunogenicity and durability of immune responses, potentially leading to the development of next-generation rotavirus vaccines with improved performance characteristics. As technological innovations continue to drive progress in vaccine development, the global human rotavirus vaccine market is poised for further growth and innovation, with the potential to achieve even greater impact in reducing the global burden of rotavirus gastroenteritis.
Restraints:
- Vaccine Hesitancy and Accessibility
- Cost of Vaccination Programs
-
Challenges in Distribution and Storage-Challenges in distribution and storage pose significant hurdles to the global human rotavirus vaccine market, particularly in regions with limited healthcare infrastructure and resources. Rotavirus vaccines, primarily administered orally, require cold chain storage to maintain their efficacy and stability. However, maintaining the cold chain throughout the vaccine distribution process, from manufacturing facilities to remote healthcare centers, presents logistical challenges, including the need for reliable refrigeration equipment, trained personnel, and adequate transportation infrastructure. In resource-limited settings, where electricity and refrigeration facilities may be scarce, ensuring the integrity of the cold chain becomes even more challenging, increasing the risk of vaccine degradation and wastage.
The decentralized nature of vaccine distribution systems in many countries exacerbates the challenges of ensuring timely and equitable access to rotavirus vaccines. In fragmented healthcare systems, vaccines may be stored and distributed through multiple channels, including public health facilities, private clinics, and community outreach programs. Coordinating these diverse distribution channels and maintaining consistent vaccine supply chains requires effective collaboration between government agencies, healthcare providers, and vaccine manufacturers. However, logistical inefficiencies, bureaucratic hurdles, and supply chain disruptions can lead to vaccine stockouts, uneven distribution, and delays in vaccine delivery, hindering efforts to achieve high vaccination coverage rates and protect vulnerable populations from rotavirus infections.
The high cost of implementing and maintaining cold chain infrastructure poses financial barriers to vaccine distribution and storage, particularly in low- and middle-income countries. Investments in refrigeration equipment, transportation logistics, and staff training can strain limited healthcare budgets, diverting resources from other essential health services. Additionally, the need for specialized storage facilities and temperature monitoring systems adds to the overall cost of vaccine distribution, further challenging the sustainability of rotavirus vaccination programs. Addressing these challenges in distribution and storage requires coordinated efforts from policymakers, healthcare stakeholders, and international organizations to improve cold chain infrastructure, strengthen supply chain management, and enhance vaccine accessibility in resource-constrained settings.
Opportunities:
- Expansion in Low- and Middle-Income Countries
- Innovations in Vaccine Delivery Systems
-
Partnerships for Improved Vaccine Access-Partnerships are playing a vital role in improving access to human rotavirus vaccines globally, particularly in low- and middle-income countries where the burden of rotavirus-related illness is most significant. Collaborations between governments, international organizations, vaccine manufacturers, and philanthropic entities aim to overcome barriers to vaccine access, including affordability, distribution challenges, and healthcare infrastructure limitations. Through strategic partnerships, initiatives such as the Gavi, the Vaccine Alliance, and the Rotavirus Vaccine Program facilitate the procurement, delivery, and implementation of rotavirus vaccination programs in underserved regions. These partnerships leverage collective resources, expertise, and networks to ensure equitable access to vaccines and maximize their impact on reducing rotavirus morbidity and mortality.
Partnerships enable capacity-building efforts to strengthen healthcare systems and vaccination infrastructure in low-resource settings. Training programs for healthcare workers, community outreach initiatives, and investments in cold chain logistics are essential components of collaborative efforts to enhance vaccine delivery and uptake. By empowering local healthcare providers and communities, partnerships foster sustainable solutions for the effective delivery and monitoring of rotavirus vaccination programs. Additionally, partnerships facilitate advocacy and communication campaigns to raise awareness about the benefits of rotavirus vaccination and address vaccine hesitancy, cultural beliefs, and misconceptions surrounding vaccination, further promoting vaccine acceptance and uptake.
Public-private partnerships are driving innovation in vaccine development, delivery systems, and affordability strategies to improve vaccine access. Collaboration between vaccine manufacturers and research institutions enables the development of more affordable vaccine formulations, heat-stable formulations, and novel delivery devices tailored to the needs of resource-limited settings. Furthermore, partnerships with regulatory agencies and procurement mechanisms streamline the regulatory approval process and facilitate bulk purchasing agreements, ensuring timely access to high-quality vaccines at affordable prices. By harnessing the strengths of diverse stakeholders and fostering collaboration across sectors, partnerships are instrumental in expanding access to human rotavirus vaccines and advancing global efforts to reduce the burden of rotavirus-related illness and mortality.
Competitive Landscape Analysis
Key players in Global Human Rotavirus Vaccine Market include:
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Bharat Biotech
- Sanofi S.A.
- Lanzhou Institute of Biological Products Co., Ltd.
- Serum Institute of India Pvt. Ltd.
- Biological E. Limited
- Shanghai Institute of Biological Products Co., Ltd.
- Hualan Biological Engineering Inc.
- Instituto Butantan
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Global Human Rotavirus Vaccine Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Emphasis on Childhood Immunization Programs
- Rising Awareness of Rotavirus Infections
- Technological Advancements in Vaccine Development
- Restraints
- Vaccine Hesitancy and Accessibility
- Cost of Vaccination Programs
- Challenges in Distribution and Storage
- Opportunities
- Vaccine Hesitancy and Accessibility
- Cost of Vaccination Programs
- Challenges in Distribution and Storage
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Human Rotavirus Vaccine Market, By Type, 2021 - 2031 (USD Million)
- Rotarix
- Rotateq
- Rotavac
- Rotavin-M1
- Lanzhou Lamb
- Other
- Global Human Rotavirus Vaccine Market, By End Use, 2021 - 2031 (USD Million)
- Hospitals & Clinics
- Academic And Research
- Others
- Global Human Rotavirus Vaccine Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Human Rotavirus Vaccine Market, By Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Bharat Biotech
- Sanofi S.A.
- Lanzhou Institute of Biological Products Co., Ltd.
- Serum Institute of India Pvt. Ltd.
- Biological E. Limited
- Shanghai Institute of Biological Products Co., Ltd.
- Hualan Biological Engineering Inc.
- Instituto Butantan
- Company Profiles
- Analyst Views
- Future Outlook of the Market